| Literature DB >> 26041702 |
Teri A Manolio1, Marc Abramowicz2, Fahd Al-Mulla3, Warwick Anderson4, Rudi Balling5, Adam C Berger6, Steven Bleyl7, Aravinda Chakravarti8, Wasun Chantratita9, Rex L Chisholm10, Vajira H W Dissanayake11, Michael Dunn12, Victor J Dzau13, Bok-Ghee Han14, Tim Hubbard15, Anne Kolbe16, Bruce Korf17, Michiaki Kubo18, Paul Lasko19, Erkki Leego20, Surakameth Mahasirimongkol21, Partha P Majumdar22, Gert Matthijs23, Howard L McLeod24, Andres Metspalu20, Pierre Meulien25, Satoru Miyano26, Yaakov Naparstek27, P Pearl O'Rourke28, George P Patrinos29, Heidi L Rehm30, Mary V Relling31, Gad Rennert32, Laura Lyman Rodriguez33, Dan M Roden34, Alan R Shuldiner35, Sukdeb Sinha36, Patrick Tan37, Mats Ulfendahl38, Robyn Ward39, Marc S Williams40, John E L Wong41, Eric D Green33, Geoffrey S Ginsburg42.
Abstract
Around the world, innovative genomic-medicine programs capitalize on singular capabilities arising from local health care systems, cultural or political milieus, and unusual selected risk alleles or disease burdens. Such individual efforts might benefit from the sharing of approaches and lessons learned in other locales. The U.S. National Human Genome Research Institute and the National Academy of Medicine recently brought together 25 of these groups to compare projects, to examine the current state of implementation and desired near-term capabilities, and to identify opportunities for collaboration that promote the responsible practice of genomic medicine. Efforts to coalesce these groups around concrete but compelling signature projects should accelerate the responsible implementation of genomic medicine in efforts to improve clinical care worldwide.Entities:
Mesh:
Year: 2015 PMID: 26041702 PMCID: PMC4898888 DOI: 10.1126/scitranslmed.aab0194
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956